# Metabolic Cofactor Supplementation in Alzheimer's Disease (AD) and Parkinson's Disease (PD) Patients

> **NCT04044131** · PHASE2 · COMPLETED · sponsor: **Istanbul Medipol University Hospital** · enrollment: 120 (actual)

## Conditions studied

- Alzheimer Disease
- Parkinson Disease

## Interventions

- **DRUG:** Metabolic Cofactor Supplementation
- **DRUG:** Sorbitol

## Key facts

- **NCT ID:** NCT04044131
- **Lead sponsor:** Istanbul Medipol University Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-12-02
- **Primary completion:** 2021-03-15
- **Final completion:** 2021-04-20
- **Target enrollment:** 120 (ACTUAL)
- **Last updated:** 2022-08-08

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04044131

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04044131, "Metabolic Cofactor Supplementation in Alzheimer's Disease (AD) and Parkinson's Disease (PD) Patients". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT04044131. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*